Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00938912 · ClinicalTrials.gov registry record · Phase 2
An Open-Label Study to Determine Safety , Tolerability, and Efficacy of Oral Lacosamide in Children With Epilepsy
A Phase 2 study, sponsored by UCB Biosciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 366
- Enrollment target
NCT00938912 is a Phase 2 study that has completed, run by UCB Biosciences. The registered enrollment target is 366 participants.
The verdict
NCT00938912, a Phase 2 study, has completed, sponsored by UCB Biosciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 366 participants
- Enrollment target
Study Summary
SP848 is an open-label study to evaluate long-term safety, tolerability, and efficacy in children with epilepsy treated with Lacosamide (LCM) oral solution (syrup) or LCM tablets as adjunctive therapy.
Interventions
- DRUG Lacosamide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 366 participants |
| Start Date | 2009-12-09 |
| Est. Completion | 2021-05-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00938912
The ClinicalTrials.gov registry entry for NCT00938912 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 366 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCB Biosciences, which has 39 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lacosamide is the first listed.
NCT00938912 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00938912 about?
NCT00938912 is a clinical study titled "An Open-Label Study to Determine Safety , Tolerability, and Efficacy of Oral Lacosamide in Children With Epilepsy". SP848 is an open-label study to evaluate long-term safety, tolerability, and efficacy in children with epilepsy treated with Lacosamide (LCM) oral solution (syrup) or LCM tablets as adjunctive therapy.
What is the current status of trial NCT00938912?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 366 participants. The study started on 2009-12-09. Estimated completion is 2021-05-18.
What interventions are being tested in trial NCT00938912?
The interventions under investigation include: Lacosamide (DRUG).
Who is sponsoring clinical trial NCT00938912?
This trial is sponsored by UCB Biosciences, which has 39 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.